City Therapeutics, Inc. (CTY)
City Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet

City Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024
Period EndingJun '26 Dec '25 Dec '24
Revenue
14.3413.562.78
Revenue Growth
-388.19%-
Gross Profit
14.3413.562.78
Operating Income
-84.46-59.92-29.09
Net Income
-87.67-58.51-27.84

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024
Period EndingJun '26 Dec '25 Dec '24
Cash & Investments
169.61112.79126.9
Total Debt
57.0467.2822.3
Net Cash (Debt)
112.5745.51104.6
Net Cash Growth
--56.49%-

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024
Period EndingJun '26 Dec '25 Dec '24
Operating Cash Flow
-77.67-41.61-20.39
Capital Expenditures
-3.08-2.41-3.54
Free Cash Flow
-80.75-44.02-23.93
Free Cash Flow Growth
---

Margins

Fiscal YearTTMFY 2025FY 2024
Period EndingJun '26 Dec '25 Dec '24
Gross Margin
100.00%100.00%100.00%
Operating Margin
-588.90%-441.84%-1047.16%
Pretax Margin
-611.25%-431.39%-1002.02%
Profit Margin
-611.25%-431.39%-1002.02%
FCF Margin
-563.00%-324.55%-861.34%